PL3003330T4 - Terapia przywracająca mikrobiota (MRT), kompozycje i sposoby wytwarzania - Google Patents
Terapia przywracająca mikrobiota (MRT), kompozycje i sposoby wytwarzaniaInfo
- Publication number
- PL3003330T4 PL3003330T4 PL14742388T PL14742388T PL3003330T4 PL 3003330 T4 PL3003330 T4 PL 3003330T4 PL 14742388 T PL14742388 T PL 14742388T PL 14742388 T PL14742388 T PL 14742388T PL 3003330 T4 PL3003330 T4 PL 3003330T4
- Authority
- PL
- Poland
- Prior art keywords
- mrt
- compositions
- manufacture
- methods
- restoration therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0278—Physical preservation processes
- A01N1/0284—Temperature processes, i.e. using a designated change in temperature over time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B25/00—Packaging other articles presenting special problems
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B7/00—Closing containers or receptacles after filling
- B65B7/02—Closing containers or receptacles deformed by, or taking-up shape, of, contents, e.g. bags, sacks
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361831409P | 2013-06-05 | 2013-06-05 | |
EP14742388.3A EP3003330B1 (en) | 2013-06-05 | 2014-06-04 | Microbiota restoration therapy (mrt), compositions and methods of manufacture |
PCT/US2014/040856 WO2014197562A1 (en) | 2013-06-05 | 2014-06-04 | Microbiota restoration therapy (mrt), compositions and methods of manufacture |
Publications (2)
Publication Number | Publication Date |
---|---|
PL3003330T4 true PL3003330T4 (pl) | 2019-03-29 |
PL3003330T3 PL3003330T3 (pl) | 2019-03-29 |
Family
ID=51220860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL14742388T PL3003330T3 (pl) | 2013-06-05 | 2014-06-04 | Terapia przywracająca mikrobiota (MRT), kompozycje i sposoby wytwarzania |
Country Status (17)
Country | Link |
---|---|
US (12) | US9675648B2 (pl) |
EP (3) | EP3003330B1 (pl) |
JP (2) | JP6330032B2 (pl) |
KR (3) | KR102093537B1 (pl) |
CN (2) | CN114099553A (pl) |
AU (5) | AU2014275025B2 (pl) |
CA (1) | CA2914636C (pl) |
DK (1) | DK3003330T3 (pl) |
ES (1) | ES2673581T3 (pl) |
HR (1) | HRP20181302T1 (pl) |
HU (1) | HUE040211T2 (pl) |
IL (2) | IL242934B (pl) |
LT (1) | LT3003330T (pl) |
PL (1) | PL3003330T3 (pl) |
PT (1) | PT3003330T (pl) |
SI (1) | SI3003330T1 (pl) |
WO (1) | WO2014197562A1 (pl) |
Families Citing this family (141)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3181684B1 (en) | 2010-02-01 | 2019-05-29 | Rebiotix Inc. | Bacteriotherapy for clostridium difficile colitis |
NZ607043A (en) | 2010-08-04 | 2015-05-29 | Borody Thomas J | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
HK1253538A1 (zh) * | 2010-08-04 | 2019-06-21 | Borody Thomas J | 用於糞便菌群植入的組合物及其製備和使用方法 |
US10245288B2 (en) | 2011-02-04 | 2019-04-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease |
US11357722B2 (en) | 2011-02-04 | 2022-06-14 | Seed Health, Inc. | Method and system for preventing sore throat in humans |
US10583033B2 (en) | 2011-02-04 | 2020-03-10 | Katherine Rose Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
US10548761B2 (en) | 2011-02-04 | 2020-02-04 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
US10010568B2 (en) | 2011-02-04 | 2018-07-03 | Katherine Rose Kovarik | Method and system for reducing the likelihood of a spirochetes infection in a human being |
US10085938B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for preventing sore throat in humans |
US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US10111913B2 (en) | 2011-02-04 | 2018-10-30 | Joseph E. Kovarik | Method of reducing the likelihood of skin cancer in an individual human being |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11273187B2 (en) | 2015-11-30 | 2022-03-15 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing depression in an individual |
US10687975B2 (en) | 2011-02-04 | 2020-06-23 | Joseph E. Kovarik | Method and system to facilitate the growth of desired bacteria in a human's mouth |
US11191665B2 (en) | 2011-02-04 | 2021-12-07 | Joseph E. Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
US10835560B2 (en) | 2013-12-20 | 2020-11-17 | Joseph E. Kovarik | Reducing the likelihood of skin cancer in an individual human being |
US10842834B2 (en) | 2016-01-06 | 2020-11-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US9987224B2 (en) | 2011-02-04 | 2018-06-05 | Joseph E. Kovarik | Method and system for preventing migraine headaches, cluster headaches and dizziness |
US10086018B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
US11523934B2 (en) | 2011-02-04 | 2022-12-13 | Seed Health, Inc. | Method and system to facilitate the growth of desired bacteria in a human's mouth |
US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
WO2012122478A1 (en) | 2011-03-09 | 2012-09-13 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
JP6330032B2 (ja) | 2013-06-05 | 2018-05-23 | レビオティクス インコーポレイテッドRebiotix,Inc. | 微生物叢回復療法組成物を製造、処理、および梱包するための方法 |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US9754080B2 (en) | 2014-10-21 | 2017-09-05 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions |
US10395777B2 (en) | 2014-10-21 | 2019-08-27 | uBiome, Inc. | Method and system for characterizing microorganism-associated sleep-related conditions |
US10793907B2 (en) | 2014-10-21 | 2020-10-06 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions |
US11783914B2 (en) | 2014-10-21 | 2023-10-10 | Psomagen, Inc. | Method and system for panel characterizations |
US10409955B2 (en) | 2014-10-21 | 2019-09-10 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions |
US10073952B2 (en) | 2014-10-21 | 2018-09-11 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions |
US10388407B2 (en) | 2014-10-21 | 2019-08-20 | uBiome, Inc. | Method and system for characterizing a headache-related condition |
US10346592B2 (en) | 2014-10-21 | 2019-07-09 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues |
US10311973B2 (en) | 2014-10-21 | 2019-06-04 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions |
US10357157B2 (en) | 2014-10-21 | 2019-07-23 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features |
US10381112B2 (en) | 2014-10-21 | 2019-08-13 | uBiome, Inc. | Method and system for characterizing allergy-related conditions associated with microorganisms |
CA2962466C (en) | 2014-10-21 | 2023-01-10 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics |
US10777320B2 (en) | 2014-10-21 | 2020-09-15 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions |
US9760676B2 (en) | 2014-10-21 | 2017-09-12 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions |
US10789334B2 (en) | 2014-10-21 | 2020-09-29 | Psomagen, Inc. | Method and system for microbial pharmacogenomics |
US10410749B2 (en) | 2014-10-21 | 2019-09-10 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions |
US10325685B2 (en) | 2014-10-21 | 2019-06-18 | uBiome, Inc. | Method and system for characterizing diet-related conditions |
US10169541B2 (en) | 2014-10-21 | 2019-01-01 | uBiome, Inc. | Method and systems for characterizing skin related conditions |
US9710606B2 (en) | 2014-10-21 | 2017-07-18 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues |
US9758839B2 (en) | 2014-10-21 | 2017-09-12 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features |
US10265009B2 (en) | 2014-10-21 | 2019-04-23 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features |
US10366793B2 (en) | 2014-10-21 | 2019-07-30 | uBiome, Inc. | Method and system for characterizing microorganism-related conditions |
GB201421735D0 (en) * | 2014-12-07 | 2015-01-21 | Craig Nicola M | Humanized gut microbiota |
SG11201704811YA (en) | 2014-12-23 | 2017-07-28 | 4D Pharma Res Ltd | Immune modulation |
BR112017013274A2 (pt) | 2014-12-23 | 2018-02-06 | 4D Pharma Research Limited | polipeptídeo e imunomodulação |
US10246753B2 (en) | 2015-04-13 | 2019-04-02 | uBiome, Inc. | Method and system for characterizing mouth-associated conditions |
WO2016172196A1 (en) | 2015-04-20 | 2016-10-27 | Pätzold Bernhard | Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains |
FR3035328B1 (fr) * | 2015-04-24 | 2019-08-23 | Maat Pharma | Procede de preparation d'un echantillon de microbiote fecal |
FR3035317B1 (fr) | 2015-04-24 | 2019-06-14 | Maat Pharma | Dispositif de prelevement de micro-organismes, kit de prelevement comprenant un tel dispositif et procede de prelevement mettant en œuvre un tel dispositif |
WO2016178775A1 (en) * | 2015-05-01 | 2016-11-10 | Microbiome Health Research Institute Inc. | Compositions and methods for therapeutic delivery of microbial communities |
AU2016202831B2 (en) * | 2015-05-08 | 2021-11-18 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
CN114990099A (zh) | 2015-05-11 | 2022-09-02 | 迈彼欧提克斯制药有限公司 | 用于使益生菌在使细菌于肠道中定植用途的固体颗粒上生长成益生菌生物膜的***和方法 |
DK3297644T3 (da) * | 2015-05-22 | 2022-04-11 | Univ Arizona State | Fremgangsmåder til behandling af autismespektrumforstyrrelse og forbundne symptomer |
US10905726B2 (en) | 2015-06-09 | 2021-02-02 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
ES2889902T3 (es) * | 2015-06-09 | 2022-01-14 | Rebiotix Inc | Métodos de fabricación de composiciones para terapia de restauración de la microbiota (TRM) |
US10799539B2 (en) | 2015-06-09 | 2020-10-13 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
US10828340B2 (en) | 2015-06-09 | 2020-11-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
SI3307288T1 (sl) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Spojine, ki vsebujejo bakterijske seve |
NZ737752A (en) | 2015-06-15 | 2022-02-25 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
CN115364122A (zh) | 2015-06-15 | 2022-11-22 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
CN108368539A (zh) | 2015-09-10 | 2018-08-03 | 生命技术公司 | 环境或生物样本中的核酸纯化 |
CN105219645B (zh) * | 2015-11-06 | 2018-09-25 | 南京农业大学 | 一种微生物保护剂及其应用 |
CN112569262A (zh) | 2015-11-20 | 2021-03-30 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
US10086024B2 (en) | 2015-11-30 | 2018-10-02 | Joseph E. Kovarik | Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides |
US10675347B2 (en) | 2015-11-30 | 2020-06-09 | Joseph E. Kovarik | Method and system for protecting honey bees from fipronil pesticides |
US10933128B2 (en) | 2015-11-30 | 2021-03-02 | Joseph E. Kovarik | Method and system for protecting honey bees from pesticides |
US11529412B2 (en) | 2015-11-30 | 2022-12-20 | Seed Health, Inc. | Method and system for protecting honey bees from pesticides |
US10568916B2 (en) | 2015-11-30 | 2020-02-25 | Joseph E. Kovarik | Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides |
FR3045383B1 (fr) | 2015-12-18 | 2019-06-14 | Maat Pharma | Procede de lyophilisation d'un echantillon de microbiote fecal |
EP3413902A4 (en) * | 2016-02-11 | 2019-11-13 | Nubyiota LLC | SYSTEMS AND METHOD FOR CHARACTERIZING COMPOSITIONS WITH BACTERIAL POPULATIONS FROM FECALIA |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
CN108883139B (zh) | 2016-03-04 | 2022-04-26 | 4D制药有限公司 | 包含细菌菌株的组合物 |
MX2018013808A (es) | 2016-05-13 | 2019-03-28 | Rebiotix Inc | Metodo analitico para cuantificacion de bacterias viables contenidas en composiciones para terapia de restauracion de microbiota (mrt). |
EP3463403A4 (en) * | 2016-05-25 | 2020-04-15 | Mybiotics Pharma Ltd | COMPOSITION AND METHODS FOR TREATMENT WITH A MICROBIOTE |
US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
US20180036352A1 (en) * | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
US20210275603A1 (en) * | 2016-10-11 | 2021-09-09 | Crestovo Holdings Llc | Compositions and Methods for Treating Irritable Bowel Syndrome and Related Disorders |
US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
US20200188449A1 (en) * | 2016-10-11 | 2020-06-18 | Crestovo Holdings Llc | Compositions and Methods for Treating Chronic Fatigue Syndrome and Related Disorders |
ES2894498T3 (es) | 2016-10-19 | 2022-02-14 | S Biomedic Nv | Métodos y composiciones para cambiar la composición del microbioma de la piel usando mezclas complejas de cepas bacterianas |
AU2017370681A1 (en) * | 2016-12-06 | 2019-06-27 | Pendulum Therapeutics, Inc. | Methods and compositions relating to isolated and purified microbes |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
US11400121B2 (en) * | 2017-01-05 | 2022-08-02 | The University Of Chicago | Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA) |
EP3570855A1 (en) | 2017-01-19 | 2019-11-27 | Pleonova AB | Autologous fecal sample for use in the treatment of microbial dysbiosis |
JPWO2018155614A1 (ja) * | 2017-02-23 | 2019-12-19 | 株式会社大塚製薬工場 | 腸内細菌叢抽出容器 |
DE102017203234B4 (de) | 2017-02-28 | 2018-11-15 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Mikrobiom-Transplantation |
WO2018187272A1 (en) | 2017-04-03 | 2018-10-11 | Gusto Global, Llc | Rational design of microbial-based biotherapeutics |
WO2018187464A1 (en) * | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
CA3058818A1 (en) * | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating parkinson's disease (pd) and related disorders |
MA48939B1 (fr) | 2017-05-22 | 2021-06-30 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
AU2018272048B2 (en) | 2017-05-26 | 2024-04-04 | Finch Therapeutics Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
JP6837581B2 (ja) | 2017-06-14 | 2021-03-03 | フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited | Megasphaera属の細菌株を含む組成物及びその使用 |
RS61210B1 (sr) | 2017-06-14 | 2021-01-29 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
US20200360450A1 (en) * | 2017-08-07 | 2020-11-19 | Finch Therapeutics, Inc. | Treatment of liver disease by modulation of the microbiome |
CA3072032A1 (en) | 2017-08-07 | 2019-02-14 | Finch Therapeutics, Inc. | Compositions and methods for maintaining and restoring a healthy gut barrier |
EP3665181A4 (en) * | 2017-08-07 | 2021-06-09 | Finch Therapeutics, Inc. | COMPOSITIONS AND PROCEDURES FOR DECOLONIZATION OF ANTIBIOTIC-RESISTANT BACTERIA IN THE INTESTINAL |
EP3443967A1 (de) * | 2017-08-17 | 2019-02-20 | Labor L + S Aktiengesellschaft | Verfahren zur einlagerung der bakterienflora des darms eines lebewesens, insbesondere eines menschen |
WO2019075426A1 (en) | 2017-10-13 | 2019-04-18 | Rebiotix, Inc. | MICROBIOM HEALTH INDEX |
FR3078627B1 (fr) | 2018-03-09 | 2020-11-13 | Maat Pharma | Procedure de collecte de selles et procede de preparation d'un echantillon pour transplantation de microbiote fecal |
WO2019213595A1 (en) * | 2018-05-04 | 2019-11-07 | Ferring B.V. | Microbiota restoration therapy (mrt) compositions and methods of manufacture |
WO2019241523A1 (en) | 2018-06-14 | 2019-12-19 | Rebiotix, Inc. | Microbiota restoration therapy (mrt) compositions and methods of manufacture |
US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
WO2020018668A1 (en) | 2018-07-17 | 2020-01-23 | Ferring B.V. | Combination therapy comprising microbiota restoration therapy (mrt) compositions |
KR20210065969A (ko) | 2018-09-27 | 2021-06-04 | 핀치 테라퓨틱스 홀딩스 엘엘씨 | 간질 및 관련 장애를 치료하기 위한 조성물 및 방법 |
WO2020086413A1 (en) * | 2018-10-26 | 2020-04-30 | Locus Oil Ip Company, Llc | Personalized system for restoring the gastrointestinal tract microbiome |
US10709744B1 (en) | 2019-03-28 | 2020-07-14 | Mybiotics Pharma Ltd. | Probiotic biofilm suppositories |
KR20220000398A (ko) | 2019-04-12 | 2022-01-03 | 로커스 아이피 컴퍼니 엘엘씨 | 향상된 탄소 격리 및 가축 생산 온실 가스 배출 감소를 위한 목초지 처리 |
US11763920B2 (en) | 2019-07-31 | 2023-09-19 | Dig Labs Corporation | Mucus analysis for animal health assessments |
CN114175178A (zh) | 2019-07-31 | 2022-03-11 | 迪格实验室公司 | 动物健康评估 |
CR20220257A (es) * | 2019-11-11 | 2023-01-17 | Sabine Hazan | Equipo de muestra de heces para tratamiento de un individuo con una condición de salud con trasplante de microbiota fecal |
KR102296880B1 (ko) * | 2019-12-04 | 2021-09-02 | 주식회사 쓰임받는사람들 | 입체 그림물감 |
EP3838269A1 (en) | 2019-12-16 | 2021-06-23 | European Molecular Biology Laboratory | Compounds and pharmaceutical compositions for prevention and/or treatment of dysbiosis and antibacterial antidotes for microbiome-protection |
WO2021130181A1 (en) * | 2019-12-23 | 2021-07-01 | Lauridsen Hengameh Chloe | Novel faecal composition |
EP4081189A1 (en) * | 2019-12-23 | 2022-11-02 | Hengameh Chloe Lauridsen | Capsule comprising a faecal composition |
US11744866B2 (en) | 2020-03-18 | 2023-09-05 | Sabine Hazan | Methods of preventing and treating COVID-19 infection with probiotics |
CN111534466B (zh) * | 2020-05-14 | 2021-06-04 | 深圳市融思生物科技有限公司 | 一种人类粪便肠道菌群样本的处理方法及处理试剂 |
JP2023527876A (ja) | 2020-06-01 | 2023-06-30 | フェリング ベスローテン フェンノートシャップ | 膣内微生物叢組成物 |
WO2022036225A1 (en) | 2020-08-14 | 2022-02-17 | Prolacta Bioscience, Inc. | Human milk oligosaccharide compositions for use with bacteriotherapies |
WO2022051610A1 (en) | 2020-09-04 | 2022-03-10 | Ferring B.V. | Microbiota restoration therapy (mrt) compositions and methods of manufacture |
WO2024006500A1 (en) * | 2022-07-01 | 2024-01-04 | Patternag, Inc. | Compositions and methods for stabilizing biological materials |
Family Cites Families (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL257275A (pl) | 1959-10-26 | |||
US3261761A (en) * | 1962-05-07 | 1966-07-19 | Arthur W Anderson | Method of freeze drying bacterial cultures |
US5196205A (en) | 1987-10-12 | 1993-03-23 | Borody Thomas J | Method for treatment of gastro intestinal disorders |
WO1989005659A1 (en) | 1987-12-24 | 1989-06-29 | Borody Thomas J | Orthostatic lavage solutions |
US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
ATE165738T1 (de) | 1988-08-02 | 1998-05-15 | Gastro Services Pty Ltd | Behandlung von gastro-intestinalen krankheiten |
CA1337265C (en) | 1988-08-04 | 1995-10-10 | Thomas Julius Borody | Oral antibody therapy for patients with lowered immune response and composition therefor |
CA2051092C (en) | 1990-09-12 | 2002-07-23 | Stephen A. Livesey | Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions |
JP3425441B2 (ja) | 1990-10-22 | 2003-07-14 | ガストロ サービシイズ ピーティーワイ リミテッド | 非炎症性及び非感染性腸障害の処置 |
US5519014A (en) | 1990-10-22 | 1996-05-21 | Borody; Thomas J. | Treatment of non-inflammatory and non-infectious bowel disorders |
US5229374A (en) | 1992-01-28 | 1993-07-20 | Burton Albert F | Method for treatment of lower gastrointestinal tract disorders |
JPH05292943A (ja) * | 1992-04-23 | 1993-11-09 | Nakano Vinegar Co Ltd | 微生物の保存方法 |
JP3025931B2 (ja) | 1993-07-07 | 2000-03-27 | 大塚製薬株式会社 | 表皮細胞シートの凍結保存用液 |
US5599795A (en) | 1994-08-19 | 1997-02-04 | Mccann; Michael | Method for treatment of idiopathic inflammatory bowel disease (IIBD) |
AUPM864894A0 (en) | 1994-10-07 | 1994-11-03 | Borody, Thomas Julius | Treatment of bowel-dependent neurological disorders |
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US5656283A (en) | 1995-06-08 | 1997-08-12 | Ortho Pharmaceutical Corporation | In-situ lyophilization of vaginal suppository in unit dose applicator and resultant product |
CA2232001C (en) | 1995-09-15 | 2002-12-10 | Dale N. Gerding | Methods and compositions for prevention and treatment of clostridium difficile-associated diseases |
US6103268A (en) | 1995-11-03 | 2000-08-15 | Borody; Thomas Julius | Administering osmotic colonic evacuant containing a picosulfate |
AUPN634595A0 (en) | 1995-11-03 | 1995-11-30 | Borody, Thomas Julius | Improved method for colonic evacuation |
US5925354A (en) | 1995-11-30 | 1999-07-20 | Michigan State University | Riboflavin mutants as vaccines against Actinobacillus pleuropneumoniae |
US5711446A (en) | 1996-01-16 | 1998-01-27 | Sorenson Bioscience, Inc. | Cryogenic freezing vial |
US5902578A (en) | 1996-03-25 | 1999-05-11 | Abbott Laboratories | Method and formula for the prevention of diarrhea |
US5837238A (en) | 1996-06-05 | 1998-11-17 | Biogaia Biologics Ab | Treatment of diarrhea |
US6096310A (en) | 1997-04-15 | 2000-08-01 | Bier; Milan | Oral immunotherapy of bacterial overgrowth |
AUPO665397A0 (en) | 1997-05-07 | 1997-05-29 | Borody, Thomas Julius | Novel therapy for constipation |
AU754270B2 (en) | 1997-10-20 | 2002-11-07 | Sanofi Pasteur Biologics, Llc | Passive immunization against clostridium difficile disease |
US6969520B2 (en) | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
US6179823B1 (en) * | 1998-01-20 | 2001-01-30 | Bracco Research Usa | Multiple use universal connector flexible medical container assembly |
US6179822B1 (en) * | 1998-01-20 | 2001-01-30 | Bracco Research Usa | Single use universal access device/medical container assembly |
US6428783B1 (en) | 1998-03-11 | 2002-08-06 | Medtech Center, Inc. | Bank of autochthonous strains of microorganisms and methods of its use for recovery of intestinal microbiocenosis of the men |
US6461607B1 (en) | 1998-08-24 | 2002-10-08 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
AU6499299A (en) * | 1998-09-21 | 2000-04-10 | 21St Century Medicine, Inc. | Polyvinyl alcohol compounds for inhibition of ice growth |
ID29150A (id) | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
US7430478B2 (en) | 2000-03-01 | 2008-09-30 | Caridian Bct, Inc. | Blood processing information system with blood loss equivalency tracking |
FR2808689B1 (fr) | 2000-05-11 | 2004-09-03 | Agronomique Inst Nat Rech | Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs |
JP2001327280A (ja) * | 2000-05-23 | 2001-11-27 | Lion Corp | 菌用凍結保存液 |
US20040062757A1 (en) | 2001-06-05 | 2004-04-01 | Finegold Sydney M. | Method of testing gastrointestinal diseases associated with species of genus clostridium |
US20040170617A1 (en) | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
US20020013270A1 (en) | 2000-06-05 | 2002-01-31 | Bolte Ellen R. | Method for treating a mental disorder |
WO2001097821A1 (en) | 2000-06-19 | 2001-12-27 | Mucoprotec Pty Ltd | Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor. |
AU2001272369A1 (en) | 2000-07-17 | 2002-01-30 | Chr. Hansen A/S | Methods and formultations with probiotic microorganisms and medicaments |
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
US7192724B2 (en) | 2000-11-14 | 2007-03-20 | Techlab, Inc. | Method for differentiating irritable bowel syndrome from inflammatory bowel disease (IBD) and for monitoring persons with IBD using total endogenous lactoferrin as a marker |
CA2451955C (en) | 2001-06-26 | 2015-09-29 | Abgenix, Inc. | Antibodies to opgl |
DK1432786T3 (da) | 2001-09-06 | 2009-10-26 | Rapid Micro Biosystems Inc | Hurtig detektion af replikerede celler |
EP1300472A1 (en) | 2001-10-02 | 2003-04-09 | Stichting Top-Instituut Voedselwetenschappen | A method for testing the effect of nutrients on gastrointestinal colonisation resistance of humans |
GB0124580D0 (en) | 2001-10-12 | 2001-12-05 | Univ Reading | New composition |
US20030154105A1 (en) | 2001-12-10 | 2003-08-14 | Ferguson Martin L. | Systems and methods for obtaining data correlated patient samples |
US20030161871A1 (en) | 2001-12-19 | 2003-08-28 | Geoffrey Hird | Solubilized riboflavin |
AUPS088702A0 (en) | 2002-03-04 | 2002-03-28 | Borody, Thomas Julius | Electrolyte purgative |
ATE513551T1 (de) | 2003-01-24 | 2011-07-15 | Flora Technology Inc | Zusammensetzungen und verfahren zur wiederherstellung der bakterienflora |
GB0322791D0 (en) | 2003-09-30 | 2003-10-29 | Lifeforce Group Plc | Blood co-processing for contingent autologous leukocyte transplantation |
US20050239706A1 (en) | 2003-10-31 | 2005-10-27 | Washington University In St. Louis | Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject |
US20060008511A1 (en) | 2004-07-08 | 2006-01-12 | Jhy-Jhu Lin | Probiotic products for pet applications |
US7935334B2 (en) | 2005-07-07 | 2011-05-03 | Imagilin Technologies, LLC | Probiotics as alternative medicines against infectious diseases |
US7909806B2 (en) * | 2004-09-23 | 2011-03-22 | Anthrogenesis Corporation | Cord blood and placenta collection kit |
EP1817432A2 (en) | 2004-10-05 | 2007-08-15 | Wyeth a Corporation of the State of Delaware | Probe arrays for detecting multiple strains of different species |
MX2007005491A (es) | 2004-11-08 | 2007-09-27 | Univ Yale | Diseno de compuesto basado en la estructura que involucra riboconmutadores. |
US20060276769A1 (en) * | 2004-12-23 | 2006-12-07 | John Domkowski | Medical fluid container |
US20060210448A1 (en) | 2005-03-10 | 2006-09-21 | Naishu Wang | Fecal specimen collection, preserving and transport device and method |
US7607776B1 (en) | 2005-10-24 | 2009-10-27 | James Waller Lambuth Lewis | Digital eye bank for virtual clinic trials |
US8313901B2 (en) | 2005-12-21 | 2012-11-20 | Yale University | Methods and compositions related to the modulation of riboswitches |
ATE541469T1 (de) | 2005-12-29 | 2012-02-15 | Hills Pet Nutrition Inc | Verfahren zum modifizieren der darmflora bei tieren |
US20080027353A1 (en) | 2006-07-31 | 2008-01-31 | Kliman Harvey J | Method of making and using a library of biological information |
JP2010505580A (ja) * | 2006-10-13 | 2010-02-25 | リライアンス ライフ サイエンシーズ ピーヴィーティー. リミテッド | 生体高分子上での培養メラニン細胞 |
WO2008076696A2 (en) | 2006-12-18 | 2008-06-26 | Washington University In St. Louis | The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder |
CN100519738C (zh) | 2007-02-02 | 2009-07-29 | 丽珠医药集团股份有限公司 | 一种双歧杆菌活菌制剂及其专用保护剂 |
EP2030623A1 (en) | 2007-08-17 | 2009-03-04 | Nestec S.A. | Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria |
WO2009042642A2 (en) * | 2007-09-24 | 2009-04-02 | President And Fellows Of Harvard College | Compositions and methods for the treatment and prevention of ulcerative colitis and colon cancer |
US20090148540A1 (en) | 2007-12-10 | 2009-06-11 | Mi Hope Incorporated | Antibacterial composition and method of production |
WO2009120347A2 (en) | 2008-03-27 | 2009-10-01 | Memorial Sloan Kettering Cancer Center | Modulators of rna riboswitches |
EP2310532B1 (en) | 2008-06-30 | 2014-05-07 | The Washington University | Methods of promoting weight loss and associated arrays |
US20100008850A1 (en) | 2008-07-14 | 2010-01-14 | William John Martin | Method of generating hydrogen in drinking water using an enerceutical product added to magnesium in a hydrogen permeable but solute impermeable container |
CN104247718A (zh) | 2008-07-17 | 2014-12-31 | 生物工厂公司 | 利用绿木霉物种与根际活性的哈茨木霉物种的组合来控制植物疾病与增强植物生长 |
US20120077781A1 (en) | 2008-08-11 | 2012-03-29 | Robert Gadwood | Flavin derivatives |
JP5525280B2 (ja) * | 2009-02-19 | 2014-06-18 | 裕昭 乾 | 細胞をガラス化保存する方法および細胞のガラス化保存用容器 |
GB0916335D0 (en) | 2009-09-17 | 2009-10-28 | Martin W J | Medicaments |
EP2480255B1 (en) | 2009-09-23 | 2017-11-22 | Thomas Julius Borody | Therapy for chronic enteric infections |
US8999360B2 (en) | 2009-10-22 | 2015-04-07 | Thomas Julius Borody | Compositions and methods for treating extracellular parasitic infections |
CA2778181A1 (en) | 2009-10-26 | 2011-05-05 | Thomas Julius Borody | Therapy for enteric infections |
EP3181684B1 (en) | 2010-02-01 | 2019-05-29 | Rebiotix Inc. | Bacteriotherapy for clostridium difficile colitis |
US8853269B2 (en) | 2010-02-04 | 2014-10-07 | Copperhead Chemical Company Inc. | Composition and method for treating infections and promoting intestinal health |
FI20105478A0 (fi) | 2010-04-30 | 2010-04-30 | Valtion Teknillinen | Menetelmä tyypin 1 diabeteksen diagnosoimiseksi ja menetelmiä ja koostumuksia tyypin 1 diabeteksen puhkeamisen estämiseksi |
US9707207B2 (en) | 2010-05-26 | 2017-07-18 | The United States Of America As Represented By The Department Of Veterans Affairs | Method for diagnosing, preventing, and treating neurological diseases |
WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性t細胞の増殖または集積を誘導する作用を有する組成物 |
WO2012013861A2 (en) | 2010-07-26 | 2012-02-02 | Suomen Punainen Risti Veripalvelu | Use of blood group status iii |
FI20105825A (fi) | 2010-07-26 | 2012-01-27 | Suomen Punainen Risti Veripalvelu | Veriryhmästatuksen käyttö III |
NZ607043A (en) | 2010-08-04 | 2015-05-29 | Borody Thomas J | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US9386793B2 (en) | 2010-08-20 | 2016-07-12 | New York University | Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota |
AU2011299285B2 (en) | 2010-09-10 | 2017-01-05 | Ntcd, Llc | Environmental Clostridial bacteriotherapy and related formulations and methods of manufacture and use |
WO2014152484A1 (en) * | 2013-03-14 | 2014-09-25 | Regents Of The University Of Minnesota | Freeze dried fecal microbiota for use in fecal microbial transplantation |
WO2012122478A1 (en) | 2011-03-09 | 2012-09-13 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
WO2012122522A2 (en) | 2011-03-09 | 2012-09-13 | Washington University | Cultured collection of gut microbial community |
WO2012142605A1 (en) | 2011-04-15 | 2012-10-18 | Samaritan Health Services | Rapid recolonization deployment agent |
US20120276060A1 (en) | 2011-04-29 | 2012-11-01 | Techlab, Inc. | Fecal lactoferrin as a biomarker for determining disease severity and for treating infection in patients with clostridium difficile disease |
US20130022575A1 (en) | 2011-07-19 | 2013-01-24 | Microbial Rx | Systems and methods of replacing intestinal flora |
WO2013032538A1 (en) | 2011-08-26 | 2013-03-07 | Microbiota Diagnostics, Llc | Methods for diagnosing and treating cardiac defects |
EP2750682B1 (en) | 2011-10-11 | 2016-05-18 | Achim Biotherapeutics AB | Composition comprising anaerobically cultivated human intestinal microbiota |
US9176026B2 (en) | 2011-12-15 | 2015-11-03 | Pureflora, Inc. | Device for the collection, refinement, and administration of gastrointestinal microflora |
EP2636684A1 (en) | 2012-03-09 | 2013-09-11 | CSL Behring AG | Prevention of infection |
US9421233B2 (en) | 2012-04-27 | 2016-08-23 | Cedars-Sinai Medical Center | Fungal mycobiome as probiotics, diagnostics and therapeutics |
US10130665B2 (en) | 2012-05-18 | 2018-11-20 | Genome Research Limited | Method for identifying bacteria for bacteriotherapy |
US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
EP3628161B1 (en) | 2012-11-23 | 2023-04-05 | Seres Therapeutics, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
WO2014078911A1 (en) | 2012-11-26 | 2014-05-30 | Borody Thomas J | Compositions for the restoration of a fecal microbiota and methods for making and using them |
US9689602B2 (en) * | 2012-12-23 | 2017-06-27 | Illuminate Consulting, Llc | Method and apparatus for thermally protecting and/or transporting temperature sensitive products |
EP3904502A3 (en) | 2013-02-04 | 2022-02-23 | Seres Therapeutics, Inc. | Compositions and methods |
CN110917220A (zh) | 2013-02-04 | 2020-03-27 | 赛里斯治疗公司 | 治疗组合物及其使用方法 |
US9192361B2 (en) | 2013-02-26 | 2015-11-24 | Christopher J Stevens | Fecal microbiome transplant material preparation method and apparatus |
US9511100B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US9694039B2 (en) | 2013-06-05 | 2017-07-04 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US10383901B2 (en) | 2013-06-05 | 2019-08-20 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
JP6330032B2 (ja) | 2013-06-05 | 2018-05-23 | レビオティクス インコーポレイテッドRebiotix,Inc. | 微生物叢回復療法組成物を製造、処理、および梱包するための方法 |
US9782445B2 (en) | 2013-06-05 | 2017-10-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US9511099B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
DK3297644T3 (da) | 2015-05-22 | 2022-04-11 | Univ Arizona State | Fremgangsmåder til behandling af autismespektrumforstyrrelse og forbundne symptomer |
US10905726B2 (en) | 2015-06-09 | 2021-02-02 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
ES2889902T3 (es) | 2015-06-09 | 2022-01-14 | Rebiotix Inc | Métodos de fabricación de composiciones para terapia de restauración de la microbiota (TRM) |
US10799539B2 (en) | 2015-06-09 | 2020-10-13 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
US10828340B2 (en) | 2015-06-09 | 2020-11-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
-
2014
- 2014-06-04 JP JP2016517952A patent/JP6330032B2/ja active Active
- 2014-06-04 EP EP14742388.3A patent/EP3003330B1/en not_active Revoked
- 2014-06-04 CN CN202111357079.XA patent/CN114099553A/zh active Pending
- 2014-06-04 PL PL14742388T patent/PL3003330T3/pl unknown
- 2014-06-04 CN CN201480044316.9A patent/CN105473152A/zh active Pending
- 2014-06-04 KR KR1020167000098A patent/KR102093537B1/ko active IP Right Grant
- 2014-06-04 WO PCT/US2014/040856 patent/WO2014197562A1/en active Application Filing
- 2014-06-04 KR KR1020207007721A patent/KR102291174B1/ko active IP Right Grant
- 2014-06-04 DK DK14742388.3T patent/DK3003330T3/en active
- 2014-06-04 AU AU2014275025A patent/AU2014275025B2/en active Active
- 2014-06-04 CA CA2914636A patent/CA2914636C/en active Active
- 2014-06-04 ES ES14742388.3T patent/ES2673581T3/es active Active
- 2014-06-04 EP EP23172424.6A patent/EP4234011A3/en active Pending
- 2014-06-04 HU HUE14742388A patent/HUE040211T2/hu unknown
- 2014-06-04 SI SI201430828T patent/SI3003330T1/sl unknown
- 2014-06-04 KR KR1020177037164A patent/KR102099503B1/ko active IP Right Grant
- 2014-06-04 PT PT14742388T patent/PT3003330T/pt unknown
- 2014-06-04 LT LTEP14742388.3T patent/LT3003330T/lt unknown
- 2014-06-04 US US14/295,686 patent/US9675648B2/en active Active
- 2014-06-04 EP EP18170305.9A patent/EP3375447A1/en active Pending
- 2014-06-30 US US14/319,852 patent/US9433651B2/en active Active
- 2014-08-15 US US14/461,027 patent/US20140363400A1/en not_active Abandoned
-
2015
- 2015-04-17 US US14/689,464 patent/US10603341B2/en active Active
- 2015-11-12 US US14/939,669 patent/US9642880B2/en active Active
- 2015-12-03 IL IL242934A patent/IL242934B/en active IP Right Grant
-
2016
- 2016-08-17 US US15/239,287 patent/US10610547B2/en active Active
-
2017
- 2017-02-27 AU AU2017201330A patent/AU2017201330B2/en active Active
- 2017-05-10 US US15/591,758 patent/US10391129B2/en active Active
- 2017-06-07 JP JP2017112144A patent/JP6363259B2/ja active Active
- 2017-06-09 US US15/618,718 patent/US10624932B2/en active Active
- 2017-06-16 US US15/625,715 patent/US10471107B2/en active Active
- 2017-06-22 US US15/630,234 patent/US10493111B2/en active Active
-
2018
- 2018-08-09 HR HRP20181302TT patent/HRP20181302T1/hr unknown
- 2018-08-23 AU AU2018220114A patent/AU2018220114B2/en active Active
- 2018-11-21 IL IL263175A patent/IL263175B/en active IP Right Grant
-
2020
- 2020-04-07 US US16/841,791 patent/US11554143B2/en active Active
- 2020-04-22 AU AU2020202691A patent/AU2020202691B2/en active Active
-
2022
- 2022-06-22 AU AU2022204369A patent/AU2022204369A1/en active Pending
- 2022-12-07 US US18/062,934 patent/US20230210912A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL263175B (en) | Microbiota restoration therapy (mrt) compounds and methods of manufacture | |
IL281424A (en) | Microbiota restoration treatment preparations and production methods | |
IL254016A0 (en) | A preparation for medical and preventive treatment produced by microbiota | |
EP2991946A4 (en) | Pumice-containing remedial compositions and methods of use | |
IL286759A (en) | Therapeutic methods and preparations | |
EP2836224A4 (en) | COMPOSITIONS OF BIOZOOSE AND RELATED METHODS | |
EP3038646A4 (en) | Diagnostic methods and compositions for treatment of glioblastoma | |
GB201320723D0 (en) | Composition and methods of treatment | |
EP3035933A4 (en) | Compositions and therapeutic methods for accelerated plaque regression | |
EP3021839A4 (en) | Methods and compositions for treatment of fibrosis | |
IL239840A0 (en) | Polymyxins, preparations, methods of preparation and methods of use | |
EP3035934A4 (en) | Compositions and therapeutic methods for accelerated plaque regression | |
EP2988764A4 (en) | COMPOSITIONS AGAINST DANDRUFF AND METHOD FOR USE THEREOF | |
EP3071214A4 (en) | Salacia compositions, methods of treatment by their administration, and methods of their preparation | |
HK1220374A1 (zh) | 用於治療碳氧血紅蛋白血症的組合物和方法 | |
EP3057596A4 (en) | Compositions and methods of administering same | |
EP2994147A4 (en) | Compositions and methods for the treatment of tinnitus | |
IL244537A0 (en) | New administration preparations and methods of their use | |
EP3080246A4 (en) | Compositions and methods for producing and administering brown adipocytes | |
EP3016981A4 (en) | Compositions and methods for treatment of stroke | |
EP2988737A4 (en) | Methods and compositions for treating diseases | |
AU2013903955A0 (en) | Compositions and Methods of Administering Same | |
AU2013902004A0 (en) | Compositions for Therapy and Methods of Treatment | |
AU2013901658A0 (en) | Compositions and methods for the treatment of tinnitus | |
AU2013904774A0 (en) | Methods and Preparation and Use of Xanthorrhoeaceae Compositions |